scholarly journals The effect of acetylsalicylic acid dosed at bedtime on the anti-aggregation effect in patients with coronary heart disease and arterial hypertension: A randomized, controlled trial

2020 ◽  
Vol 26 (6) ◽  
pp. 727-735 ◽  
Author(s):  
Beata Krasińska ◽  
Lech Paluszkiewicz ◽  
Ewa Miciak-Lawicka ◽  
Maciej Krasiński ◽  
Piotr Rzymski ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Randomized Controlled Trial ◽  
Heart Disease ◽  
Arterial Hypertension ◽  
Acetylsalicylic Acid ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Aggregation Effect

scholarly journals Effectiveness of eHealth cardiac rehabilitation on health outcomes of coronary heart disease patients: a randomized controlled trial protocol

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Jing Jing Su ◽  
Doris Sau Fung Yu
Keyword(s):  
Coronary Heart Disease ◽  
Randomized Controlled Trial ◽  
Heart Disease ◽  
Health Outcomes ◽  
Cardiac Rehabilitation ◽  
Controlled Trial ◽  
Hybrid Approach ◽  
Lifestyle Interventions ◽  
Randomized Controlled ◽  
Preparatory Phase

Abstract Background Cardiac rehabilitation (CR) uptake and adherence remain sub-optimal despite the apparent health benefits of modifying healthy behavior and slowing disease progression. eHealth is the use of information and communication technology (ICT) for health. eHealth lifestyle interventions and disease management have emerged as modalities to enhance CR accessibility, enable an individualized progress page, and enrich real-time contact, video-based information, and technology monitored functionality. This study aims to develop a nurse-led eHealth cardiac rehabilitation (NeCR) intervention and investigate its effectiveness on coronary heart disease (CHD) patients’ health outcomes. Methods This single-blinded two-arm parallel randomized controlled trial will randomize 146 patients from the inpatient cardiovascular units of a hospital in Wuhan, China to receive either the NeCR or the usual care. The NeCR intervention uses a hybrid approach consisting of a brief face-to-face preparatory phase and an empowerment phase delivered by health technology. The preparatory phase aims at identifying self-care needs, developing a goal-oriented patient centered action plan, incorporating a peer support network and orientation to the use of the e-platform. The empowerment phase includes use of the multi-media interactive NeCR for promoting symptom management, monitoring lifestyle changes and offering psychological support. A tele-care platform is also integrated to enhance health care dialogue with health professionals and peer groups. The control group will receive the usual care. An evaluation of lifestyle behavioral changes, self-efficacy, health-related quality of life, anxiety and depression, cardiovascular risk parameters, and unplanned health services use will be conducted at baseline, 6 weeks and 12 weeks post-intervention. Discussion This protocol proposes an individualized, comprehensive, and interactive NeCR delivered using a hybrid approach and guided by an empowerment model to optimize health outcomes of CHD patients. The intervention content and web-design is based on international health guidelines to improve credibility, comprehensibility and implementation. This study also proposes a new method of peer support in which the researcher shares participants’ progress toward goal attainment with the peer group. Results of this research have the potential to increase accessibility and availability of CR, improve cardiac rehabilitation service development in China, and inform eHealth lifestyle interventions. Trial registration Chinese Clinical Trial Registry: ChiCTR1800020411; Date of registration: December 28, 2018.

scholarly journals Effects of Astragalus injection and Salvia Miltiorrhiza injection on serum inflammatory markers in patients with stable coronary heart disease: a randomized controlled trial study

2019 ◽  
Author(s):  
Luo Zhihao ◽  
Yuntao Liu ◽  
Zhen Zhao ◽  
Xia Yan ◽  
Dawei Wang ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Randomized Controlled Trial ◽  
Heart Disease ◽  
Salvia Miltiorrhiza ◽  
Controlled Trial ◽  
Tanshinone Iia ◽  
Fatty Acid Binding ◽  
Randomized Controlled ◽  
Stable Coronary Heart Disease ◽  
Main Component

Abstract Background: Coronary heart disease (CHD) is a clinical syndrome caused by coronary atherosclerosis (AS) or functional changes of coronary arteries. Our previous experimental study found that the main component of Astragalus, Astragaloside IV, and the main component of Salvia Miltiorrhiza, Tanshinone IIA, can effectively improve myocardial ischemic injury. Methods: This study was a prospective, randomized, blinded, parallel design trial. A total of 160 eligible patients were randomized to a treatment group (in three groups) or the placebo control group in a 1:1:1:1 ratio using a central randomization system. Patients will receive appropriate treatment for 7 days within 24 hours after enrollment and follow-up for 28 days. Main evaluation indicators: cell count, serum high-sensitivity C-reactive protein (hs-CRP) level, monocyte chemoattractant protein 1 (MCP-1), Interleukin-6(IL-6), IL-1β, IL-8, IL-18, IL-10, Tumor necrosis factor(TNF-α), Oxidized low density lipoprotein(OX-LDL), exosome levels, and angina grade and Traditional Chinese Medicine (TCM) symptom changes scale. Secondary evaluation indicators: B-type natriuretic peptide (BNP) level, troponin (cTn), muscle enzyme isoenzyme (CK-MB), heart-type fatty acid binding protein (H-FABP), liver function, renal function, blood coagulation and the like. Adverse events will be monitored throughout the trial. Discussion: This is a randomized controlled trial of Chinese herbal extracts for the treatment of coronary heart disease. The results of this trial will provide valuable clinical evidence for the recommendations for disease management and identify its underlying mechanisms.

Sign in / Sign up

Export Citation Format

Share Document